A new diabetes monitoring pathway is designed to keep older cancer patients safe during corticosteroid therapy, addressing the risk of steroid-driven hyperglycemia in elderly cohorts. The focus is operational: clinicians need a practical monitoring plan that identifies glycemic deterioration early while treatment proceeds. The report highlights the growing attention to metabolic complications as a core part of supportive oncology care, not an afterthought.